Heidi Chen

Dec 18, 2024 | insights.citeline.com | Heidi Chen |Anabel Costa-Ferreira

Data: The Clinical Trials Space Rebounds The complex landscape of clinical trials, fraught with pressures and risks, and exacerbated by the adoption of new technologies, regulatory burdens, and drug pricing negotiations, is rebounding with aplomb.

Nov 13, 2024 | clinicalleader.com | Dan Schell |Heidi Chen |Meghan Hosely

Right-sized for biotech successIt’s not the size of your company. It’s the size of your passion and your dedication to improving patients’ lives that IQVIA Biotech is uniquely built to serve. There is nothing bigger to us than your success. We’ve got you. Using Direct-To-Patient Deliveries For Supply Chain ManagementUCB Vice President – Head of Global Clinical Science and Operations Tero Laulajainen gets us up to speed on direct-to-patient (DTP) trials and how UCB is leveraging it today.

Dec 20, 2023 | clinicalleader.com | Jocelyn Reynolds |Heidi Chen |Meghan Hosely

How Can Electronic Data Capture Better Serve Decentralized Clinical Trials? Will EDC evolve to fix its existing problems, or will a different type of DCT platform (or single platform model) replace pick-and-pull, add-and-subtract modules of clinical trial technology?

Nov 20, 2023 | invivo.citeline.com | Heidi Chen

Analysis Executive Summary In a post-pandemic world, the evolving landscape of clinical trials just got more complex. The year 2022 was one of many adjustments given the incidence of lower trial initiations. The health care industry endured the impacts of geopolitical conflicts, curbed growth in China and stagflation in major markets. You may also be interested in...  Existing Subscriber? Sign in to continue reading.

Jun 26, 2023 | clinicalleader.com | Heidi Chen

By Heidi Chen, Associate Director, Research & Commercial Services In the preceding year, researchers at Citeline highlighted the resilience and resurgence of clinical trial activity after the pandemic, with a 6% growth in total trials (22% excluding COVID-19 trials) in 2021. Fast forward one year and the roller coaster ride continued as the healthcare sector grappled with the ongoing influence of the global economy and political climate.